Literature DB >> 19889753

Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication.

Katrin Schlie1, Anna Maisa, Frank Lennartz, Ute Ströher, Wolfgang Garten, Thomas Strecker.   

Abstract

Mature glycoprotein spikes are inserted in the Lassa virus envelope and consist of the distal subunit GP-1, the transmembrane-spanning subunit GP-2, and the signal peptide, which originate from the precursor glycoprotein pre-GP-C by proteolytic processing. In this study, we analyzed the oligomeric structure of the viral surface glycoprotein. Chemical cross-linking studies of mature glycoprotein spikes from purified virus revealed the formation of trimers. Interestingly, sucrose density gradient analysis of cellularly expressed glycoprotein showed that in contrast to trimeric mature glycoprotein complexes, the noncleaved glycoprotein forms monomers and oligomers spanning a wide size range, indicating that maturation cleavage of GP by the cellular subtilase SKI-1/S1P is critical for formation of the correct oligomeric state. To shed light on a potential relation between cholesterol and GP trimer stability, we performed cholesterol depletion experiments. Although depletion of cholesterol had no effect on trimerization of the glycoprotein spike complex, our studies revealed that the cholesterol content of the viral envelope is important for the infectivity of Lassa virus. Analyses of the distribution of viral proteins in cholesterol-rich detergent-resistant membrane areas showed that Lassa virus buds from membrane areas other than those responsible for impaired infectivity due to cholesterol depletion of lipid rafts. Thus, derivation of the viral envelope from cholesterol-rich membrane areas is not a prerequisite for the impact of cholesterol on virus infectivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889753      PMCID: PMC2798336          DOI: 10.1128/JVI.02039-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  87 in total

1.  High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.

Authors:  E Kretzschmar; L Buonocore; M J Schnell; J K Rose
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Functional rafts in cell membranes.

Authors:  K Simons; E Ikonen
Journal:  Nature       Date:  1997-06-05       Impact factor: 49.962

3.  The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide.

Authors:  W Weissenhorn; S A Wharton; L J Calder; P L Earl; B Moss; E Aliprandis; J J Skehel; D C Wiley
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

4.  Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin.

Authors:  D Fass; P S Kim
Journal:  Curr Biol       Date:  1995-12-01       Impact factor: 10.834

5.  Dimerization of transcobalamin II receptor. Requirement of a structurally ordered lipid bilayer.

Authors:  S Bose; J Feix; S Seetharam; B Seetharam
Journal:  J Biol Chem       Date:  1996-05-17       Impact factor: 5.157

6.  Lipid rafts play an important role in the vesicular stomatitis virus life cycle.

Authors:  W Wang; Y J Fu; Y G Zu; N Wu; J Reichling; T Efferth
Journal:  Arch Virol       Date:  2009-03-15       Impact factor: 2.574

7.  Borna disease virus requires cholesterol in both cellular membrane and viral envelope for efficient cell entry.

Authors:  Roberto Clemente; Aymeric de Parseval; Mar Perez; Juan C de la Torre
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

8.  Hepatitis B virus infection is dependent on cholesterol in the viral envelope.

Authors:  Corinna M Bremer; Christiane Bung; Nicole Kott; Martin Hardt; Dieter Glebe
Journal:  Cell Microbiol       Date:  2008-11-05       Impact factor: 3.715

9.  Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa.

Authors:  Thomas Briese; Janusz T Paweska; Laura K McMullan; Stephen K Hutchison; Craig Street; Gustavo Palacios; Marina L Khristova; Jacqueline Weyer; Robert Swanepoel; Michael Egholm; Stuart T Nichol; W Ian Lipkin
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

10.  Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants.

Authors:  Anna Maisa; Ute Ströher; Hans-Dieter Klenk; Wolfgang Garten; Thomas Strecker
Journal:  PLoS Negl Trop Dis       Date:  2009-06-02
View more
  15 in total

1.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

2.  The role of proteolytic processing and the stable signal peptide in expression of the Old World arenavirus envelope glycoprotein ectodomain.

Authors:  Dominique J Burri; Antonella Pasquato; Joel Ramos da Palma; Sebastien Igonet; Michael B A Oldstone; Stefan Kunz
Journal:  Virology       Date:  2012-12-04       Impact factor: 3.616

3.  Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

Authors:  Kathryn M Hastie; Robert W Cross; Stephanie S Harkins; Michelle A Zandonatti; Anatoliy P Koval; Megan L Heinrich; Megan M Rowland; James E Robinson; Thomas W Geisbert; Robert F Garry; Luis M Branco; Erica Ollmann Saphire
Journal:  Cell       Date:  2019-08-08       Impact factor: 66.850

4.  Structure of the Lassa virus glycan shield provides a model for immunological resistance.

Authors:  Yasunori Watanabe; Jayna Raghwani; Joel D Allen; Gemma E Seabright; Sai Li; Felipe Moser; Juha T Huiskonen; Thomas Strecker; Thomas A Bowden; Max Crispin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

Review 5.  Multifunctional nature of the arenavirus RING finger protein Z.

Authors:  Sarah Katharina Fehling; Frank Lennartz; Thomas Strecker
Journal:  Viruses       Date:  2012-11-09       Impact factor: 5.048

Review 6.  Envelope glycoprotein of arenaviruses.

Authors:  Dominique J Burri; Joel Ramos da Palma; Stefan Kunz; Antonella Pasquato
Journal:  Viruses       Date:  2012-10-17       Impact factor: 5.048

Review 7.  Molecular mechanism of arenavirus assembly and budding.

Authors:  Shuzo Urata; Jiro Yasuda
Journal:  Viruses       Date:  2012-10-10       Impact factor: 5.048

8.  Crystal structure of Venezuelan hemorrhagic fever virus fusion glycoprotein reveals a class 1 postfusion architecture with extensive glycosylation.

Authors:  Marie-Laure Parsy; Karl Harlos; Juha T Huiskonen; Thomas A Bowden
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike.

Authors:  Sai Li; Zhaoyang Sun; Rhys Pryce; Marie-Laure Parsy; Sarah K Fehling; Katrin Schlie; C Alistair Siebert; Wolfgang Garten; Thomas A Bowden; Thomas Strecker; Juha T Huiskonen
Journal:  PLoS Pathog       Date:  2016-02-05       Impact factor: 6.823

10.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.